Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
|Articles|April 28, 2003
Cesarean birth appears to reduce risk of stress incontinence
Chicago-Women who undergo cesarean section without a trial of labor appearto be significantly less likely to experience stress urinary incontinencethan those who deliver vaginally or underwent a CS for obstructed labor,according to a study from Israel.
Advertisement
Advertisement
Related to this article
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5